ZNF711 is an X-linked zinc finger transcription factor essential for brain development and cellular differentiation. As a transcription regulator, ZNF711 binds to promoter sequences of target genes and recruits histone demethylases (PHF8 and JHDM2A) to activate expression of neurodevelopmental genes such as KDM5C 12. ZNF711 also functions as a regulatory switch in cardiac differentiation, directing progenitor commitment toward cardiomyocyte lineages through interaction with retinoic acid signaling 3. In disease contexts, ZNF711 mutations cause X-linked intellectual developmental disorder 97, characterized by mild intellectual disability and autism in approximately half of affected males, with no consistent craniofacial or neurologic findings 45. A ZNF711-specific DNA methylation signature aids clinical diagnosis. Beyond developmental disorders, ZNF711 expression alterations influence cancer chemotherapy resistance: downregulation promotes cisplatin resistance in ovarian cancer by suppressing SLC31A1-mediated drug uptake 6, while overexpression enhances carboplatin sensitivity 7. Paradoxically, ZNF711 overexpression promotes enzalutamide resistance in prostate cancer through AR pathway activation and epigenetic demethylation 8. These findings establish ZNF711 as a critical regulator with context-dependent roles in development, differentiation, and therapeutic response.